- Discover new technologies and strategies that identify new therapeutic uses for companies' existing portfolios.
- Network exclusively with Heads of Indication Expansion units & Head of External R&D from GSK, Eli Lilly, Abbott, Bayer Pharma, Sanofi, Takeda, Horizon Discovery and more.
- A de-risked way to develop a treatment quicker and cheaper that traditional drug development.
- Reposition, repurpose and reformulate your failed and shelved compounds to develop new commercial potential.
For the full agenda and speaker faculty, click here to download the brochure.
Save up to Â£1,260 by register this week – offer expires 24th August 2012
Ensure your innovations and drug candidates are maximising their potential so you can extract the full commercial value from all of your discoveries.
Register before this Friday 24th August 2012 for the final early bird offer.
For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D